617 results match your criteria Mycobacterium Xenopi


Pleuritis due to without pulmonary infection.

Access Microbiol 2022 22;4(3):000328. Epub 2022 Mar 22.

Institute of Pulmonology, Sheba Tel-HaShomer Medical Center, Ramat Gan, Israel.

Nontuberculous mycobacteria (NTM) may cause pulmonary and extra-pulmonary disease in both immunocompetent and immunocompromised patients. Pleuritis is an uncommon manifestation on NTM disease, and pleuritis caused by has only been described once before. Because it is considered to be an environmental contaminant, isolation of from bronchopulmonary secretions or other sites is often dismissed. Read More

View Article and Full-Text PDF

Novel case of empyema necessitans caused by .

BMJ Case Rep 2022 May 12;15(5). Epub 2022 May 12.

Division of Infectious Diseases, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo and VA Western New York Healthcare System, Buffalo, New York, USA.

Poorly controlled long-standing empyema can dissect through soft tissues and skin resulting in empyema necessitans. We present the first reported case of empyema necessitans caused by which was treated successfully with antimycobacterial therapy. The case highlights the indolent nature of the pathogen and the importance of an accurate diagnosis. Read More

View Article and Full-Text PDF

Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases.

Lancet Infect Dis 2022 Jul 25;22(7):e178-e190. Epub 2022 Jan 25.

National Jewish Health and University of Colorado Health Sciences, Denver, CO, USA.

The 2020 clinical practice guideline for the treatment of non-tuberculous mycobacterial pulmonary disease (NTM-PD) by the American Thoracic Society, European Respiratory Society, European Society of Clinical Microbiology and Infectious Diseases, and Infectious Diseases Society of America; and the 2017 management guideline by the British Thoracic Society covered pulmonary diseases in adults caused by Mycobacterium avium complex, Mycobacterium kansasii, Mycobacterium xenopi, and Mycobacterium abscessus. In order to provide evidence-based recommendations for the treatment of less common non-tuberculous mycobacterial (NTM) species in adult patients without cystic fibrosis or HIV infection, our expert panel group performed systematic literature searches to provide management guidance for pulmonary diseases caused by seven additional organisms: Mycobacterium chelonae, Mycobacterium fortuitum, Mycobacterium genavense, Mycobacterium gordonae, Mycobacterium malmoense, Mycobacterium simiae, and Mycobacterium szulgai. Treatment recommendations were developed by a structured consensus process. Read More

View Article and Full-Text PDF

Nontuberculous Mycobacteria under Scrutiny in the Geneva Area (2015-2020).

Respiration 2022 7;101(4):367-375. Epub 2021 Dec 7.

Division of Pulmonary Diseases, Department of Medicine, Geneva University Hospitals, Geneva, Switzerland.

Background: Nontuberculous mycobacteria (NTM) are increasingly identified in industrialized countries, and their role as pathogens is more frequently recognized. The relative prevalence of NTM strains shows an important geographical variability. Thus, establishing the local relative prevalence of NTM strains is relevant and useful for clinicians. Read More

View Article and Full-Text PDF

[ pulmonary disease:report of 3 cases and literature review].

Zhonghua Jie He He Hu Xi Za Zhi 2021 May;44(5):474-480

Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.

To analyze the clinical manifestations, radiographic characteristics and prognosis of pulmonary disease, in order to improve diagnosis and treatment of the disease. Using " pulmonary disease" as the search term, from February 15, 2007 to February 21, 2021, a total of 1 264 cases were retrieved in the PubMed database. In the Wanfang database, using " pulmonary disease" as the search term, from February 15, 2007 to February 21, 2021, no related document was retrieved. Read More

View Article and Full-Text PDF

Pharmacotherapy for nontuberculous mycobacterial pulmonary disease.

Am J Health Syst Pharm 2022 03;79(6):437-445

Creighton University School of Pharmacy and Health Professions, Omaha, NE, USA.

Purpose: To provide an updated review of the diagnosis and pharmacotherapy of nontuberculous mycobacteria pulmonary disease (NTM-PD) and summarize guideline recommendations for an interdisciplinary treatment approach.

Summary: A systemic approach was taken in which all articles in English in MEDLINE and PubMed were reviewed. The US National Library of Medicine's DailyMed database was used to assess drug package inserts. Read More

View Article and Full-Text PDF

Management of patients with pulmonary mycobacteriosis in France: a multicenter retrospective cohort study.

BMC Pulm Med 2021 Oct 26;21(1):333. Epub 2021 Oct 26.

Department of Bacteriology, CHU Montpellier, Montpellier, France.

Background: Recent studies report very low adherence of practitioners to ATS/IDSA recommendations for the treatment of nontuberculous mycobacteria pulmonary disease (NTM-PD), as well as a great variability of practices. Type of management could impact prognosis.

Methods: To evaluate management and prognosis of patients with NTM-PD cases with respect to ATS recommendations, we conducted a multicenter retrospective cohort study (18 sentinel sites distributed throughout France), over a period of six years. Read More

View Article and Full-Text PDF
October 2021

Conserved and specialized functions of Type VII secretion systems in non-tuberculous mycobacteria.

Microbiology (Reading) 2021 07;167(7)

Université Paris-Saclay, UVSQ, Inserm, Infection et inflammation, 78180, Montigny-Le-Bretonneux, France.

Non-tuberculous mycobacteria (NTM) are a large group of micro-organisms comprising more than 200 individual species. Most NTM are saprophytic organisms and are found mainly in terrestrial and aquatic environments. In recent years, NTM have been increasingly associated with infections in both immunocompetent and immunocompromised individuals, prompting significant efforts to understand the diverse pathogenic and signalling traits of these emerging pathogens. Read More

View Article and Full-Text PDF

A Rare Case of Henoch-Schönlein Purpura and Mycobacterium xenopi Pulmonary Infection.

Cureus 2021 Feb 24;13(2):e13533. Epub 2021 Feb 24.

General Surgery, Lebanese American University-Medical Center, Beirut, LBN.

Henoch-Schönlein purpura (HSP) is a small-vessel vasculitis with cutaneous, articular, gastrointestinal, and renal manifestations. Leukocytoclastic vasculitis and IgA deposits are classically found when involved skin and kidneys are biopsied. The disease's etiology remains unknown, although many bacterial and viral infections have been described as triggering factors. Read More

View Article and Full-Text PDF
February 2021

Complete Genome Sequence of Mycobacterium heckeshornense JCM 15655, Closely Related to a Pathogenic Nontuberculous Mycobacterial Species, Mycobacterium xenopi.

Microbiol Resour Announc 2021 Mar 11;10(10). Epub 2021 Mar 11.

Department of Mycobacteriology, Leprosy Research Center, National Institute of Infectious Diseases, Tokyo, Japan

is a slow-growing mycobacterial species for which pathogenic features are unclear. Here, we report the complete genome sequence of an type strain. This sequence will provide essential information for future taxonomic and comparative genome studies of these mycobacteria. Read More

View Article and Full-Text PDF

A multidisciplinary approach to the management of nontuberculous mycobacterial lung disease: a clinical perspective.

Authors:
Juzar Ali

Expert Rev Respir Med 2021 05 23;15(5):663-673. Epub 2021 Feb 23.

Section of Pulmonary/Critical Care Medicine & Allergy/Immunology, NTM-Bronchiectasis Program & Registry, University Medical Center, New Orleans, Louisiana State University Health Sciences Center, New Orleans, LA, USA.

Introduction: Management of nontuberculous mycobacterial lung disease (NTM-LD) can be encumbered by difficult diagnostic criteria and complex treatment decisions. As prevalence of this debilitating, often refractory, progressive lung disease increases globally, management must evolve beyond antimicrobials to encompass holistic and customized treatments coordinated by practitioners across various specialties.

Areas Covered: This review aims to complement the recently updated NTM-LD treatment guidelines and expand current approaches to diagnosis, treatment, and disease management in a multidisciplinary dimension. Read More

View Article and Full-Text PDF

Isolation and identification of nontuberculous mycobacteria from specimens of lower respiratory tract of transplanted patients based on the evaluation of 16SrRNA gene.

Ann Ig 2021 Mar-Apr;33(2):189-197

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Background: Nontuberculous mycobacteria are pervasive microorganisms and are often present as saprophytes in humans, animals, and the environment. Today, these bacteria are known as the most important environmental opportunists and, in the last decades, infections by nontuberculous mycobacteria have multiplied, due to increased immunodeficiency (cancer, transplant recipients, HIV).

Study Design: This study aimed to investigate the infections by nontuberculous mycobacteria in transplanted patients. Read More

View Article and Full-Text PDF
October 2021

The Benzimidazole SPR719 Shows Promising Concentration-Dependent Activity and Synergy against Nontuberculous Mycobacteria.

Antimicrob Agents Chemother 2021 03 18;65(4). Epub 2021 Mar 18.

Radboudumc Center for Infectious Diseases, Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands

Nontuberculous mycobacterial pulmonary disease (NTM-PD) is emerging worldwide. Currently recommended multidrug treatment regimens yield poor outcomes, and new drugs and regimens are direly needed. SPR719, the active moiety of SPR720, is a new benzimidazole antibiotic with limited data on antimycobacterial activity. Read More

View Article and Full-Text PDF

Vaping Associated Pulmonary Nontuberculous Mycobacteria.

Lung 2021 02 9;199(1):21-27. Epub 2021 Jan 9.

Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, 43210, USA.

Introduction: E-cigarette or vaping product use associated lung injury (EVALI) has been an important health risk in both children and adults. The pathophysiology of EVALI is not well understood. However, it is speculated that certain substances such as Vitamin E Acetate (VEA), particularly in marijuana containing vape cartridges may result in lung injury and lead to respiratory dysfunction. Read More

View Article and Full-Text PDF
February 2021

[Nontuberculous Mycobacterial Pulmonary Disease - The New ATS/ERS/ESCMID/IDSA Guideline].

Authors:
D Wagner C Lange

Pneumologie 2020 Nov 17;74(11):773-779. Epub 2020 Nov 17.

Medizinische Klinik, Forschungszentrum Borstel, Leibniz Lungenzentrum.

The new ATS/ERS/ESCMID/IDSA guideline answers 22 PICO questions on the treatment of lung diseases caused by complex (MAC), , and .

Non-tuberculous Mycobacteria (ntm) Lung Disease:  Especially in patients with microscopic detection of acid-fast bacteria in sputum or with cavernous disease manifestation, the start of treatment should not be delayed. Treatment should be based on species-specific resistance testing (according to the CLSI guidelines). Read More

View Article and Full-Text PDF
November 2020

Non tuberculous mycobacteria related spondylodiscitis: a case report and systematic literature review.

Infez Med 2020 Sep;28(3):425-435

UOC Chirurgia Vertebrale, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Istituto di Clinica Ortopedica, Università Cattolica del Sacro Cuore, Rome, Italy.

Purpose: Mycobacterium xenopi and Non Tuberculous Mycobacteria (NTM) are rare causes of spondylodiscitis (SD). The aim of this study was to highlight the relevance of considering these pathogens in differential diagnosis of slow growing SD, obtaining the correct diagnosis and evaluating the key points of management and therapy approach.

Methods: A case of surgically treated Mycobacterium xenopi SD is reported. Read More

View Article and Full-Text PDF
September 2020

Diagnostic performance of real time PCR and MALDI-TOF in the detection of nontuberculous mycobacteria from clinical isolates.

Tuberculosis (Edinb) 2020 12 1;125:101988. Epub 2020 Sep 1.

Department of Microbiology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, India. Electronic address:

This study aimed to evaluate the performance of real-time PCR (qPCR) and MALDI-TOF for accurate and timely detection of nontuberculous mycobacterium (NTM) from clinical isolates. We collected fifty NTM suspected Mycobacteria Growth Indicator Tube (MGIT) cultures and analysed the diagnostic performance of qPCR and VITEK MS using Line Probe Assay (LPA) GenoType CM (Common Mycobacteria) as gold standard. The qPCR assays targeting 16S rRNA, ITS and IS6110 genes were developed for the identification of NTM and Mycobacterium tuberculosis complex (MTBC). Read More

View Article and Full-Text PDF
December 2020

Disseminated Mycobacterium xenopi in an Adult with IL-12Rβ1 Deficiency.

J Clin Immunol 2020 11 27;40(8):1166-1170. Epub 2020 Aug 27.

Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla 3, 50134, Florence, FI, Italy.

View Article and Full-Text PDF
November 2020

Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.

Clin Infect Dis 2020 08;71(4):905-913

Divisions of Infectious Diseases, Schools of Public Health and Medicine, Oregon Health and Science University, Portland, Oregon, USA.

Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi among the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Read More

View Article and Full-Text PDF

[Nontuberculous mycobacterial pulmonary disease - The new ATS/ERS/ESCMID/IDSA Guideline].

Dtsch Med Wochenschr 2020 08 13;145(16):1145-1151. Epub 2020 Aug 13.

Medizinische Klinik, Forschungszentrum Borstel, Leibniz Lungenzentrum.

The new ATS/ERS/ESCMID/IDSA guideline answers 22 PICO questions on the treatment of lung diseases caused by complex (MAC), and .

Non-tuberculous Mycobacteria (ntm) Lung Disease: Especially in patients with microscopic detection of acid-fast bacteria in sputum or with cavernous disease manifestation, the start of treatment should not be delayed. Treatment should be based on species-specific resistance testing (according to the CLSI guidelines). Read More

View Article and Full-Text PDF

Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.

Eur Respir J 2020 07 7;56(1). Epub 2020 Jul 7.

Divisions of Infectious Diseases, Schools of Public Health and Medicine, Oregon Health and Science University, Portland, OR, USA.

Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as complex, , and among the slowly growing NTM and among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Read More

View Article and Full-Text PDF

Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.

Clin Infect Dis 2020 08;71(4):e1-e36

Divisions of Infectious Diseases, Schools of Public Health and Medicine, Oregon Health and Science University, Portland, Oregon, USA.

Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi among the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Read More

View Article and Full-Text PDF

Use of MALDI-TOF MS (Bruker Daltonics) for identification of Mycobacterium species isolated directly from liquid medium.

Enferm Infecc Microbiol Clin (Engl Ed) 2021 05 12;39(5):241-243. Epub 2020 Jun 12.

Servicio de Microbiología, Hospital Universitario Miguel Servet. IIS Aragón, Zaragoza, Spain; Grupo de estudio de las Infecciones por Micobacterias (GEIM), Sociedad Española de Microbiología y Enfermedades Infecciosas, Spain.

Objectives: The aim of this study was to describe the evaluation of the use of MALDI-TOF MS for the identification of non-tuberculous mycobacteria (NTM) and Mycobacterium tuberculosis directly from liquid MGIT cultures from January 2017 to December 2017.

Material/methods: A total of 155 isolates (mainly respiratory) were analyzed by MALDI-TOF MS (Bruker Daltonics) directly from MGIT liquid medium with a previous extraction procedure.

Results: MALDI-TOF MS generated acceptable scores for 152 isolates (98. Read More

View Article and Full-Text PDF

A case of pulmonary infection in a healthy Japanese man.

Respir Med Case Rep 2020 16;30:101093. Epub 2020 May 16.

Division of Respirology, Neurology and Rheumatology, Department of Medicine, Kurume University School of Medicine, Fukuoka, 830-0011, Japan.

A 72-year-old man, healthy, smoker, with long-standing cough, was referred to our hospital and his chest X-ray (CXR) revealed a cavity lesion in the right upper lobe. Direct sputum smears, but not culture in solid medium, were positive for acid-fast bacilli (AFB) without tuberculosis DNA. The preliminary diagnosis was of a non-tuberculosis infection that progressed slowly, and the CXR showed the condition to worsen daily. Read More

View Article and Full-Text PDF

[Pathological characteristics and molecular diagnosis of non-tuberculosis lung disease].

Zhonghua Bing Li Xue Za Zhi 2020 Jun;49(6):562-567

Department of Pathology, Beijing Chest Hospital, Capital Medical University; Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.

To investigate the clinicopathological features of non-tuberculosis mycobacterial lung disease and the role of molecular pathology in diagnosis. Forty-five formalin-fixed, paraffin embedded (FFPE) specimens were collected from the Department of Pathology, Beijing Chest Hospital from February 2016 to August 2019. The clinical, imaging and histopathologic features, bacteriologic data and morphologic characteristics of acid fast bacilli (AFB) were analyzed retrospectively. Read More

View Article and Full-Text PDF

Clinical outcomes in Mycobacterium xenopi versus Mycobacterium avium complex pulmonary disease: A retrospective matched cohort study.

Respir Med 2020 06 15;167:105967. Epub 2020 Apr 15.

Division of Respirology, Department of Medicine, University of Toronto, Toronto, Canada; Division of Respirology, Department of Medicine, Toronto Western Hospital, Toronto, Canada.

Mycobacterium xenopi is associated with the highest mortality among pulmonary nontuberculous mycobacterial (NTM) infections, but whether this is due to the infection or other factors is unclear. There is little information regarding outcomes among patients infected with M. xenopi versus other NTM species. Read More

View Article and Full-Text PDF

Prolongation of incubation time improves clinical diagnosis of Mycobacterium xenopi infection and allows susceptibility testing of mycobacterial strains against multiple antibiotics.

J Glob Antimicrob Resist 2020 09 5;22:533-537. Epub 2020 May 5.

Chemical-clinical and Microbiological Analysis, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Objectives: Mycobacterium xenopi is a nontuberculous mycobacterium (NTM) whose clinical diagnosis and drug susceptibility studies are frequently hampered by poor in vitro growth. Extending the culture incubation time from 42 days (common-standard) to 56 days could improve the likelihood of diagnosis and provide strains for phenotypic drug susceptibility profiling of this poorly studied but clinically relevant mycobacterium.

Methods: Time-to-positivity of mycobacterial cultures incubated for 56 days were analysed and compared. Read More

View Article and Full-Text PDF
September 2020

Recent increase in non-tuberculous mycobacterial infection in patients with connective tissue diseases in Japan.

J Infect Chemother 2020 Sep 4;26(9):941-945. Epub 2020 May 4.

Department of Internal Medicine, Teikyo University, 2-11-1, Kaga, Itabashi-ku, Tokyo, Japan; National Hospital Organization Higashisaitama Hospital, Hasuda, 4147, Kurohama, Saitama, Japan.

Background: Non-tuberculous mycobacterial (NTM) infection is currently a growing health concern due to the increasing incidence and the need for prolonged therapy. In patients with connective tissue diseases, use of immunosuppressants may lead to an increased risk of NTM infection. However, few studies have examined the recent incidence of NTM infection among connective tissue diseases patients. Read More

View Article and Full-Text PDF
September 2020

Complete Genome Sequence of Mycobacterium xenopi JCM15661, Obtained Using Nanopore and Illumina Sequencing Technologies.

Microbiol Resour Announc 2020 Mar 5;9(10). Epub 2020 Mar 5.

Department of Mycobacteriology, Leprosy Research Center, National Institute of Infectious Diseases, Tokyo, Japan

is a slow-growing mycobacterial organism for which pathogenic features are unclear. Here, we report the complete genome sequence of an type strain. This sequence will provide essential information for future taxonomic and comparative genome studies of these mycobacteria. Read More

View Article and Full-Text PDF

Real-life evaluation of clinical outcomes in patients undergoing treatment for non-tuberculous mycobacteria lung disease: A ten-year cohort study.

Respir Med 2020 04 14;164:105899. Epub 2020 Feb 14.

University of Milan, Department of Pathophysiology and Transplantation, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Internal Medicine Department, Respiratory Unit, Cystic Fibrosis Adult Center, Italy.

Outcome recognition is a crucial step in the management of non-tuberculous mycobacteria lung disease (NTM-LD). In order to explore NTM-LD outcomes in a real-life setting, an observational, retrospective study enrolling consecutive adults who received treatment for NTM-LD in Milan, Italy, from 2007 to 2017 was conducted. Among 170 patients (68. Read More

View Article and Full-Text PDF